Director, HTA, Evidence, and Global Access

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 13, 2026

Salary

$240K-$265K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$61,842 U.S. median for this role

Projected growth (BLS Employment Projections)

+1.9% - Slower

U.S. benchmark only; posted salary is not compared across countries or currencies.

Matched to SOC 11-1021 - Operations aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Operations From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Work mode

Remote From the posting source checked Jun 20, 2026

In-office days

0 days From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Public-company From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, HTA, Evidence, and Global Access Remote Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. Overview As Iovance prepares to bring AMTAGVI® to patients globally outside the United States, we are seeking an individual who is experienced with HTA, Evidence, and Global Access. This role will be a critical contributor to Iovance's HTA, evidence, and global access strategies and will report to the Senior Director, Global Market Access. The position is responsible for supporting international markets where Iovance is pursuing reimbursement, planning for new indication and products, and support of commercial activities generally. Core responsibilities include end-to-end management of health technology assessment (HTA) submissions, developing Iovance's evidence generation activities, engagement with HTA bodies and payers, development of global value and access materials, and project management across global market access and HEOR activities. The role will also support HEOR-related activities -including research, economic modeling, and publications - and may from time to time engage in activities supporting projects from regulatory, commercial, or other teams. The Director will serve as the internal subject matter

Read the full description at job-boards.greenhouse.io. FewerJobs shows a preview and links to the original posting.